# Metaphore Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metaphore-biotechnologies

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.metaphorebio.com
- Total disclosed funding: $20M
- Latest round: Series A (May 16, 2023)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2021 by Lovisa Afzelius, and Daniel Acker, Metaphore Biotechnologies, Inc., a.k.a. Metaphore Biotechnologies is a biotechnology firm that develops a computationally driven bio-platform for designing new therapeutics and build its pipeline for patients with autoimmune, metabolic, or oncology indications. In April 2026, Metaphore Biotechnologies, Inc. raised an undisclosed amount of venture funding from Global BrainIn August 2026, Metaphore Biotechnologies, Inc. raised an undisclosed amount of venture funding from new investor Lotte Holdings CVC.
The company provides programming therapeutics by utilizing the MIMiC™ platform that couples machine learning with molecular mimicry. Metaphore Biotechnologies integrates parallel assays and machine learning to isolate pharmacophores for designing novel mimetic compounds where function, specificity, and selectivity are tuned and optimized.
The company plans to use the August 2026 funding to advance the development of antibody-based treatments for metabolic, immune, and vascular diseases and support its drug discovery platform.

## Funding rounds

- Series A, May 16, 2023, $20M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A